Wednesday, July 31, 2013

CAN YOU BEAT 100% IN LYMPHOMA MANAGEMENT?


Ibrutinib/R-CHOP Combination Achieves 100% Response Rate in Non-Hodgkin Lymphoma

Read more >>




Ganetespib-Docetaxel Combination Improves Survival in GALAXY-1 Trial

Read more >>




Proteins Identified as Potential Biomarkers for Response in KRAS-Mutated NSCLC


go to targeted healthcare communications for more!
targetedHC.
Post a Comment